title: Predictive factors of neutralizing antibodies development in relapsing-remitting multiple sclerosis patients on interferon Beta-1b therapy.
abstract: The identification of predictive factors of NAbs development might have a relevant impact on clinical practice. Our objective is to look after predictive factors of NAbs development in MS IFN Beta-1b-treated patients. Database was screened for patients on IFN Beta-1b treatment with an Expanded Disability Status Scale (EDSS) at a baseline between 1 and 3.5, disease duration shorter than 15 years, and NAbs analysis performed every 6 months. The NAbs positive status was analysed in relation to baseline clinical, neuropsychological and brain imaging measures. Forty-nine patients were included. Sixteen patients had become NAbs positive at some point on IFN therapy (35%). NAbs producers differed from not producers for higher incidence of cognitive deficit and higher lesion load (OR = 5.0 and 5.6, respectively). Our study suggests that NAbs development might be a marker of a more aggressive disease and that worse outcome in NAbs producers might be biased by baseline condition.
authors.affiliation: Department of Neurological Sciences, Federico II University, Via Pansini 5, Naples, Italy. robertalanzillo@libero.it
authors.forename: R
authors.initials: R
authors.lastname: Lanzillo
authors.forename: G
authors.initials: G
authors.lastname: Orefice
authors.forename: A
authors.initials: A
authors.lastname: Prinster
authors.forename: G
authors.initials: G
authors.lastname: Ventrella
authors.forename: R
authors.initials: R
authors.lastname: Liuzzi
authors.forename: V
authors.initials: V
authors.lastname: Scarano
authors.forename: C
authors.initials: C
authors.lastname: Florio
authors.forename: G
authors.initials: G
authors.lastname: Vacca
authors.forename: A
authors.initials: A
authors.lastname: Brunetti
authors.forename: B
authors.initials: B
authors.lastname: Alfano
authors.forename: V
authors.initials: V
authors.lastname: Brescia Morra
authors.forename: V
authors.initials: V
authors.lastname: Bonavita
mesh_terms: D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000293:Adolescent; D000328:Adult; D057134:Antibodies, Neutralizing / Q000096:biosynthesis*; D018450:Disease Progression; D005260:Female; D006801:Humans; D000068576:Interferon beta-1b; D016899:Interferon-beta / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy / Q000276:immunology* / Q000473:pathology; D011379:Prognosis; D012189:Retrospective Studies; D055815:Young Adult
chemical_list: D000276:Adjuvants, Immunologic; D057134:Antibodies, Neutralizing; D000068576:Interferon beta-1b; D016899:Interferon-beta